AR035759A1 - Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos - Google Patents

Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos

Info

Publication number
AR035759A1
AR035759A1 ARP020100728A ARP020100728A AR035759A1 AR 035759 A1 AR035759 A1 AR 035759A1 AR P020100728 A ARP020100728 A AR P020100728A AR P020100728 A ARP020100728 A AR P020100728A AR 035759 A1 AR035759 A1 AR 035759A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
optionally substituted
aryl
cycloalkyl
heteroaryl
Prior art date
Application number
ARP020100728A
Other languages
English (en)
Spanish (es)
Original Assignee
Telik Inc
Sanwa Kaguku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc, Sanwa Kaguku Kenkyusho Co Ltd filed Critical Telik Inc
Publication of AR035759A1 publication Critical patent/AR035759A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP020100728A 2001-03-01 2002-02-28 Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos AR035759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27279201P 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
AR035759A1 true AR035759A1 (es) 2004-07-07

Family

ID=23041292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100728A AR035759A1 (es) 2001-03-01 2002-02-28 Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos

Country Status (14)

Country Link
US (2) US6809113B2 (https=)
EP (1) EP1363897B1 (https=)
JP (1) JP4291576B2 (https=)
KR (1) KR20040018336A (https=)
CN (1) CN1259315C (https=)
AR (1) AR035759A1 (https=)
AT (1) ATE313537T1 (https=)
BR (1) BR0207750A (https=)
CA (1) CA2439849A1 (https=)
DE (1) DE60208159T2 (https=)
ES (1) ES2254653T3 (https=)
MX (1) MXPA03007861A (https=)
TW (1) TWI245761B (https=)
WO (1) WO2002070509A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1802331A2 (en) * 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
BRPI0609268A2 (pt) 2005-03-31 2010-03-09 Pfizer Prod Inc derivados de ciclopentapiridina e tetraidroquinolina
WO2007066496A1 (en) * 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited Benzoylurea compound and use thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
ES2434039T3 (es) * 2006-07-24 2013-12-13 Yeda Research And Development Co. Ltd. Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8356920B2 (en) * 2007-12-12 2013-01-22 Levine Jonathan E Lighting device
US20100152160A1 (en) * 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2522341A1 (en) * 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11351227B2 (en) * 2017-04-27 2022-06-07 Washington University Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2022326885A1 (en) * 2021-08-11 2024-02-15 Curadev Pharma Pvt. Ltd. Small molecule urea derivatives as sting antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32700B1 (en) 1968-02-03 1973-10-31 Beecham Group Ltd Penicillins
GB1250611A (https=) 1968-02-03 1971-10-20
DE2131034A1 (de) 1971-06-23 1973-01-11 Hoechst Ag Acylharnstoffe und verfahren zu ihrer herstellung
DE2652004C3 (de) 1976-11-15 1979-09-13 Basf Ag, 6700 Ludwigshafen l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US4163784A (en) 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
JP2650055B2 (ja) 1988-11-28 1997-09-03 キヤノン株式会社 電子写真感光体
FR2672888B1 (fr) 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
JPH09255572A (ja) 1996-03-26 1997-09-30 Takeda Chem Ind Ltd ケモカイン受容体拮抗剤
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd CHEMOKIN RECEPTOR ANTAGONISTS
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
EP1060166A1 (de) 1998-02-03 2000-12-20 Boehringer Ingelheim Pharma KG 5-gliedrige benzokondensierte heterocyclen als antithrombotika
WO2000006550A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6316449B1 (en) 1999-07-08 2001-11-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists
WO2001057021A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives

Also Published As

Publication number Publication date
JP2004527503A (ja) 2004-09-09
WO2002070509A3 (en) 2003-05-30
US20030105085A1 (en) 2003-06-05
ES2254653T3 (es) 2006-06-16
KR20040018336A (ko) 2004-03-03
JP4291576B2 (ja) 2009-07-08
WO2002070509A8 (en) 2003-11-06
CN1494539A (zh) 2004-05-05
MXPA03007861A (es) 2004-10-15
BR0207750A (pt) 2004-03-23
DE60208159D1 (de) 2006-01-26
US7297696B2 (en) 2007-11-20
EP1363897A2 (en) 2003-11-26
ATE313537T1 (de) 2006-01-15
DE60208159T2 (de) 2006-08-17
HK1060728A1 (en) 2004-08-20
US20050054668A1 (en) 2005-03-10
EP1363897B1 (en) 2005-12-21
CN1259315C (zh) 2006-06-14
WO2002070509A2 (en) 2002-09-12
US6809113B2 (en) 2004-10-26
CA2439849A1 (en) 2002-09-12
TWI245761B (en) 2005-12-21

Similar Documents

Publication Publication Date Title
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR035743A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos y procesos para la preparacion de dichos compuestos.
AR035801A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
UA84022C2 (ru) Производные (тио)карбамоилциклогексана как антагонисты d3/d2 рецептора
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR049333A1 (es) Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
BR0215017A (pt) Lactamas como antagonistas da taquiquinina
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR063374A1 (es) Derivados de benzoxazina y sus usos
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
RU2007125661A (ru) Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
YU18404A (sh) Hemijska jedinjenja
HRP20080097T3 (en) Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists

Legal Events

Date Code Title Description
FB Suspension of granting procedure